UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
April 11, 2005
----------------------
Date of Report (Date of earliest event reported)
OSI PHARMACEUTICALS, INC.
-------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-15190 13-3159796
---------------- --------- --------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation) File Number) Identification No.)
58 South Service Road
Melville, NY 11747
----------------------------------------
(Address of principal executive offices)
(631) 962-2000
--------- ---------------
(Registrant's telephone number, including area code)
N/A
--------------------------------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a- 12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
ITEM 8.01 OTHER EVENTS
On April 11, 2005, Genentech, Inc., OSI Pharmaceuticals, Inc.'s partner
for the distribution and sale in the United States of its oncology drug,
Tarceva (TM), announced that the net sales of Tarceva for the quarter ended
March 31, 2005 were $47.6 million.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: April 11, 2005 OSI PHARMACEUTICALS, INC.
By: /s/ Robert L. Van Nostrand
-------------------------------------
Robert L. Van Nostrand
Vice President and Chief Financial
Officer (Principal Financial Officer)
3